Promising therapeutic agents for the treatment of Parkinson’s disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Promising therapeutic agents for the treatment of Parkinson’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 6, Pages 787-799
Publisher
Informa Healthcare
Online
2016-03-10
DOI
10.1517/14712598.2016.1164687
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
- (2015) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- Prediagnostic presentations of Parkinson's disease in primary care: a case-control study
- (2015) Anette Schrag et al. LANCET NEUROLOGY
- Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
- (2015) R.T. Bartus et al. NEUROBIOLOGY OF DISEASE
- The Golden Retriever Lifetime Study: establishing an observational cohort study with translational relevance for human health
- (2015) Michael K. Guy et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
- (2014) Elena Dragicevic et al. BRAIN
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs
- (2014) Livia Dézsi et al. Expert Opinion on Drug Metabolism & Toxicology
- Safinamide for the treatment of Parkinson's disease
- (2014) Livia Dézsi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mavoglurant as a treatment for Parkinson’s disease
- (2014) Dmitry Petrov et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nanocarriers in Gene Therapy: A Review
- (2014) Hongpan Xu et al. Journal of Biomedical Nanotechnology
- Network modulation following sham surgery in Parkinson’s disease
- (2014) Ji Hyun Ko et al. JOURNAL OF CLINICAL INVESTIGATION
- Aging Decreases L-Type Calcium Channel Currents and Pacemaker Firing Fidelity in Substantia Nigra Dopamine Neurons
- (2014) S. Y. Branch et al. JOURNAL OF NEUROSCIENCE
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- (2014) Stéphane Palfi et al. LANCET
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- The prevalence of Parkinson's disease: A systematic review and meta-analysis
- (2014) Tamara Pringsheim et al. MOVEMENT DISORDERS
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
- (2014) Olivier Rascol et al. PARKINSONISM & RELATED DISORDERS
- Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study
- (2014) Yen-Chieh Lee et al. PLoS One
- Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
- (2013) Raymond T Bartus et al. MOLECULAR THERAPY
- Trophic Factor Gene Therapy for Parkinson's Disease
- (2013) Jeffrey H. Kordower et al. MOVEMENT DISORDERS
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Which dyskinesia scale best detects treatment response?
- (2013) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
- (2013) R. T. Bartus et al. NEUROLOGY
- Gene-based Therapies in Parkinson’s Disease
- (2013) Patricia J. Allen et al. Neurotherapeutics
- Genetics of Parkinson's disease: the yield
- (2013) Marianna Spatola et al. PARKINSONISM & RELATED DISORDERS
- Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease
- (2012) Dénes Zádori et al. JOURNAL OF NEURAL TRANSMISSION
- Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
- (2012) Wanqiang Chen et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues
- (2012) Fredric P. Manfredsson et al. NEUROBIOLOGY OF DISEASE
- An Update on Gene Therapy in Parkinson’s Disease
- (2011) Jennifer Witt et al. Current Neurology and Neuroscience Reports
- Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists
- (2011) Nikoletta Szabó et al. Expert Opinion on Drug Metabolism & Toxicology
- Kynurenines in Parkinson’s disease: therapeutic perspectives
- (2011) Dénes Zádori et al. JOURNAL OF NEURAL TRANSMISSION
- Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach
- (2011) Nikoletta Szabó et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
- (2011) Peter A LeWitt et al. LANCET NEUROLOGY
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- (2011) E. Ilijic et al. NEUROBIOLOGY OF DISEASE
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration
- (2010) K. Araki et al. ACTA NEUROLOGICA SCANDINAVICA
- Gene Therapy in Parkinsonʼs Disease
- (2010) Li Rebekah Feng et al. CNS DRUGS
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations
- (2010) Carlo Colosimo et al. MOVEMENT DISORDERS
- Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
- (2010) Tanya Simuni et al. MOVEMENT DISORDERS
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease
- (2010) Francisco Valles et al. NEUROSURGERY
- L-type calcium channel blockers and Parkinson's disease in Denmark
- (2009) Beate Ritz et al. ANNALS OF NEUROLOGY
- Novel therapeutic strategies in Parkinson’s disease
- (2009) Peter Klivenyi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Glutamate, excitotoxicity, and programmed cell death in parkinson disease
- (2009) W. Michael Caudle et al. EXPERIMENTAL NEUROLOGY
- Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
- (2009) C. W. Christine et al. NEUROLOGY
- Personality, Addiction, Dopamine: Insights from Parkinson's Disease
- (2009) Alain Dagher et al. NEURON
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
- (2009) B. Jarraya et al. Science Translational Medicine
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Peripheral cytokines profile in Parkinson’s disease
- (2008) M. Reale et al. BRAIN BEHAVIOR AND IMMUNITY
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
- (2008) J. L. Eberling et al. NEUROLOGY
- Use of antihypertensives and the risk of Parkinson disease
- (2008) C. Becker et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now